STN Structure Search (Registry/Caplus)

chain bonds :
2-7 3-6 4-11 7-8 8-9 8-10 8-13 11-12 13-14
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
2-7 3-4 3-6 4-11 7-8 8-9 8-10 8-13 11-12 13-14
exact bonds :
1-2 1-5 2-3 4-5
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:Atom 12:Atom 13:CLASS 14:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 19:09:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 153 TO ITERATE

100.0% PROCESSED 153 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2318 TO 3802

```
=> s l1 full
FULL SEARCH INITIATED 19:10:08 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      3156 TO ITERATE

100.0% PROCESSED     3156 ITERATIONS                    125 ANSWERS
SEARCH TIME: 00.00.01

L3          125 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             172.55     172.76

FILE 'CAPLUS' ENTERED AT 19:10:12 ON 18 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 18 Sep 2007  VOL 147 ISS 13
FILE LAST UPDATED: 17 Sep 2007  (20070917/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4            4 L3

=> d ibib abs hitstr 1-4
```

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:394818 CAPLUS
DOCUMENT NUMBER: 142:447111
TITLE: Preparation of sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
INVENTOR(S): Han, Wei; Hu, Zilun; Gungor, Timur
PATENT ASSIGNEE(S): Bristol Myers Squibb Company, USA
SOURCE: U.S. Pat. Appl. Publ., 120 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005096309	A1	20050505	US 2004-952396	20040928
US 7169795	B2	20070130		
WO 2005048922	A2	20050602	WO 2004-US31774	20040929
WO 2005048922	A3	20070104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1667635	A2	20060614	EP 2004-817779	20040929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 2007099922	A1	20070503	US 2006-611195	20061215

PRIORITY APPLN. INFO.:
US 2003-507177P P 20030930
US 2004-952396 A 20040928
WO 2004-US31774 W 20040929

OTHER SOURCE(S): MARPAT 142:447111
GI

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The present application describes sulfonylaminovalerolactams and derivs. thereof of formula I-VI or pharmaceutically acceptable salt forms thereof [wherein the central lactam ring is optionally substituted; ring G = (un)substituted mono- or bicyclic carbocycle or heterocycle; X = SO2, (un)substituted NH; G1 = H, cyano, each (un)substituted (CH2)1-2-C(O)H, NH2, (CH2)2-5-NH2, (CH2)2-5-OH, C1-6 alkyl, etc.; G2 = (un)substituted CH2CH2 or CH:CH; A = each (un)substituted C3-10 cycloalkyl, C3-10 cycloalkenyl, or 4- to 12-membered heterocyclyl; B = cyano, (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, etc.]. These compds. are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa, for treating thromboembolic disorders which is selected from arterial or venous cardiovascular thromboembolic disorders. Thus, reductive amination of cyclopentanone by (S)-6-chloronaphthalene-2-sulfonic acid N-(2-oxo-[1,4']bipiperidinyl-3-yl)amide and sodium cyanoborohydride in THF at room temperature for 5 h gave (S)-6-chloronaphthalene-2-sulfonic acid N-(1'-cyclopentyl-2-oxo-[1,4']bipiperidinyl-3-yl)amide. The compds. I inhibited factor Xa with Ki of ≤10 μM. Some of the compds. I also inhibited human thrombin with ki of ≤10 μM.

IT 851119-38-5P, (S)-6-Chloronaphthalene-2-sulfonic Acid N-[1-(1-cyclopentylpiperidin-4-yl)-2-oxopyrrolidin-3-yl]amide
851119-56-7P, (S)-6-Chloronaphthalene-2-sulfonic Acid N-[1-(1-cyclohexylpiperidin-4-yl)-2-oxopyrrolidin-3-yl]amide
851119-94-3P, (S)-6-Chloronaphthalene-2-sulfonic acid N-[1-(1-cyclopentylazetidin-3-yl)-2-oxopyrrolidin-3-yl]amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of sulfonylaminovalerolactams and derivs. thereof as factor Xa inhibitors for treating thromboembolic disorders)

RN 851119-38-5 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-(1-cyclopentyl-4-piperidinyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851119-56-7 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-(1-cyclohexyl-4-piperidinyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851119-94-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-(1-cyclopentyl-3-azetidinyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1127376 CAPLUS
DOCUMENT NUMBER: 142:74569
TITLE: Preparation of 3-sulfonylamino-pyrrolidine-2-one derivatives as factor Xa inhibitors
INVENTOR(S): Borthwick, Alan David; Kelly, Henry Anderson; Watson, Nigel Stephen; Young, Robert John
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

Instant App.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004111045	A1	20041223	WO 2004-EP6603	20040617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1641786	A1	20060405	EP 2004-740049	20040617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006527731	T	20061207	JP 2006-515993	20040617
US 2006167079	A1	20060727	US 2005-561414	20051219
PRIORITY APPLN. INFO.:			GB 2003-14373 A	20030619
			WO 2004-EP6603 W	20040617

OTHER SOURCE(S): MARPAT 142:74569
GI

6/19/03

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I II

AB Title compds. represented by the formula I [wherein R1 = (un)substituted naphthyl, benzofuryl, phenyl(alkyl), etc.; R2 = H, alkyl, alkylamido, carbonylalkyl, etc.; X = (un)substituted Ph or aromatic heterocyclic group; Y = (un)substituted Ph or aromatic heterocyclic group; and pharmaceutically acceptable derivs. thereof] were prepared as inhibitors of factor Xa. For example, II was given in a multi-step synthesis starting from the reaction of 2-fluoro-4-iodoaniline with tert-Bu ((3S)-tetrahydro-2-oxo-3-furanyl)carbamate. The prepared compds. showed activity in vitro assay for inhibition of factor Xa with Ki values of less than 100 nM. Thus, I and their pharmaceutical compns. are useful medicine, particularly in the amelioration of a clin. condition for which a factor Xa inhibitor is indicated (no data).

IT 811794-78-2P 811794-79-3P 811794-80-6P
811794-81-7P 811794-82-8P 811794-83-9P
811794-84-0P 811794-85-1P 811794-86-2P
811794-87-3P 811794-88-4P 811794-89-5P
811794-90-8P 811794-91-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-(imidazolyl)phenyl-3-(sulfonylamino)pyrrolidin-2-one derivs. as factor Xa inhibitors)

RN 811794-78-2 CAPLUS
CN 1-Propene-1-sulfonamide, N-[(3S)-1-[4-[2-(1-azetidinylmethyl)-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811794-79-3 CAPLUS
CN Formic acid, compd. with (1E)-N-[(3S)-1-[4-[2-(1-azetidinylmethyl)-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-1-propene-1-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-78-2
CMF C24 H25 Cl F N5 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 811794-80-6 CAPLUS
CN 2-Thiopheneethanesulfonamide, N-[(3S)-1-[4-[2-(1-azetidinylmethyl)-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811794-81-7 CAPLUS
CN Formic acid, compd. with N-[(3S)-1-[4-[2-(1-azetidinylmethyl)-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-5-chloro-2-thiopheneethanesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-80-6
CMF C23 H25 Cl F N5 O3 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 811794-82-8 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, N-[(3S)-1-[4-[2-(1-azetidinylmethyl)-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811794-83-9 CAPLUS
CN Formic acid, compd. with N-[(3S)-1-[4-[2-(1-azetidinylmethyl)-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-6-chlorobenzo[b]thiophene-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-82-8
CMF C25 H23 Cl F N5 O3 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 811794-84-0 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-[2-[(3-fluoro-1-pyrrolidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811794-87-3 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-[2-[(3-fluoro-1-pyrrolidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]-1-propene-1-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-86-2
CMF C25 H26 Cl F2 N5 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 811794-88-4 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-[2-[(3-fluoro-1-pyrrolidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811794-85-1 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-[2-[(3-fluoro-1-pyrrolidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]ethenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-84-0
CMF C24 H24 Cl F2 N5 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 811794-86-2 CAPLUS
CN 1-Propene-1-sulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-[2-[(3-fluoro-1-pyrrolidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811794-89-5 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-1-[2-fluoro-4-[2-[(3-fluoro-1-pyrrolidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]benzo[b]thiophene-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-88-4
CMF C26 H24 Cl F2 N5 O3 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 811794-90-8 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-[2-[(3-methoxy-1-azetidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811794-91-9 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-1-[2-fluoro-4-[2-[(3-methoxy-1-azetidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]benzo[b]thiophene-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-90-8
CMF C26 H25 Cl F N5 O4 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:20333 CAPLUS
DOCUMENT NUMBER: 140:93926
TITLE: Preparation of sulfonylaminovalerolactams as factor Xa inhibitors
INVENTOR(S): Smallheer, Joanne M.; Pinto, Donald J.; Wang, Shuaige; Qiao, Jennifer X.; Han, Wei; Hu, Zilun
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S. Pat. Appl. Publ., 89 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004006062	A1	20040108	US 2003-429461	20030505
US 7157470	B2	20070102		
WO 2004041776	A2	20040521	WO 2003-US14142	20030505
WO 2004041776	A3	20040910		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003301863	A1	20040607	AU 2003-301863	20030505
EP 1501798	A2	20050202	EP 2003-808359	20030505
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006247243	A1	20061102	US 2006-472825	20060621
PRIORITY APPLN. INFO.:			US 2002-378313P	P 20020506
			US 2003-429461	A3 20030505
			WO 2003-US14142	W 20030505

OTHER SOURCE(S): MARPAT 140:93926
GI

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I

'470 n=1



II

AB The title compds. I [G = Ph, pyridyl, pyrrolyl, etc.; G1 = H, alkyl, acyl, (substituted) amino, etc.; A = (substituted) Ph, carbocyclic, heterocyclyl; B = lactam, heterocyclyl, etc.; n = 0-2] were prepared I can be used as inhibitors of trypsin-like serine proteases, specifically factor Xa. Thus, II is prepared from 1-[4-(3-amino-2-oxopiperidin-1-yl)-3-fluorophenyl]-piperidin-2-one (preparation given) and 6-chloronaphthalene-2-sulfonyl chloride. Pharmaceutical compds. containing I are described.
IT 641612-43-3P 641612-44-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonylaminovalerolactams as factor Xa inhibitors)
RN 641612-43-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[2-oxo-1-[4-(2-oxo-1-piperidinyl)phenyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 641612-44-4 CAPLUS

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 2-Naphthalenesulfonamide, 6-chloro-N-[2-oxo-1-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

Z = Cl ✓

R^1 =  ✓

R^2 = H ✓

X = Ph ✓

Y =  ✗ Not sub. by -AkNR^{c}R^d

102(e) date 5/5/03 PCT 5/6/02 ✓

✓

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:511293 CAPLUS
DOCUMENT NUMBER: 139:85238
TITLE: Preparation of 3-(sulfonylamino)pyrrolidin-2-ones as factor Xa inhibitors
INVENTOR(S): Borthwick, Alan David; Chan, Chuen; Kelly, Henry Anderson; King, Nigel Paul; Kleanthous, Savvas; Mason, Andrew McMurtrie; Pinto, Ivan Leo; Pollard, Derek Roland; Senger, Stefan; Shah, Gita Punjabhai; Watson, Nigel Stephen; Young, Robert John
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

Applicants

7/03 X

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003053925	A1	20030703	WO 2002-EP14826	20021220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
TW 262075	B	20060921	TW 2002-91136597	20021219
CA 2471461	A1	20030703	CA 2002-2471461	20021220
AU 2002366747	A1	20030709	AU 2002-366747	20021220
EP 1456172	A1	20040915	EP 2002-805350	20021220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015200	A	20041013	BR 2002-15200	20021220
CN 1620434	A	20050525	CN 2002-828224	20021220
JP 2005519885	T	20050707	JP 2003-554642	20021220
HU 200500137	A2	20060228	HU 2005-137	20021220
NZ 533129	A	20061222	NZ 2002-533129	20021220
ZA 2004004147	A	20050621	ZA 2004-4147	20040527
IN 2004DN01467	A	20070209	IN 2004-DN1467	20040528
MX 2004PA06139	A	20041101	MX 2004-PA6139	20040621
NO 2004002990	A	20040920	NO 2004-2990	20040713
US 2005059726	A1	20050317	US 2004-499529	20041101
PRIORITY APPLN. INFO.:			GB 2001-30705	A 20011221
			WO 2002-EP14826	W 20021220

OTHER SOURCE(S): MARPAT 139:85238
GI



I II

AB Title compds. I [wherein R1 = (un)substituted naphthyl, benzothienyl, benzofuryl, indolyl, phenyl(alkyl), 2,2'-bithiophen-5-yl, thienyl(alkyl), or thieno[3,2-b]thiophenyl; R2 = H, (CH2)nCONRaRb, (CH2)nCO2Rc, morpholinoalkyl, CO2Rc, or carboxyalkyl; X = H, halo, CN, alkyl, alkenyl, CF3, NRaRb, NO2, NRcCHO, NHCORc, NHSO2Rc, alkoxyalkyl, hydroxyalkyl, CORc, CONRaRb, SO0-2Rc, SO2NRaRb, or (un)substituted Ph, heterocyclyl, or heteroaryl; n = 1-3; Ra and Rb = independently H or alkyl; or NRaRb = (un)substituted heterocyclyl; Rc = alkyl; and pharmaceutically acceptable derivs. thereof] were prepared as factor Xa inhibitors. For example, coupling of (3S)-3-amino-1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]pyrrolidin-2-one with 6-chloro-2-naphthylsulfonyl chloride in the presence of pyridine in DCM gave II. The latter inhibited human factor Xa in an in vitro fluorogenic assay with Ki <10 nM. Thus, I and compns. comprising I are useful as medicines for the amelioration of clin. conditions for which a Factor Xa inhibitor is indicated (no data).

IT 553650-52-5P, (S)-(E)-2-(5-Chlorothien-2-yl)-N-[1-[5-[2-(methylsulfonyl)phenyl]pyridin-2-yl]-2-oxopyrrolidin-3-yl]ethenesulfonamide 553650-65-0P 553650-67-2P, (S)-4'-[3-[[[(1E)-2-(5-Chlorothien-2-yl)prop-1-enyl]sulfonyl]amino]-2-oxopyrrolidin-1-yl]-3'-fluoro-1,1'-biphenyl-2-sulfonamide 553650-86-5P, (S)-3-Cyano-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]benzenesulfonamide 553650-91-2P 553651-03-9P 553651-07-3P, (S)-6-Chloro-N-[1-[2-fluoro-4-(pyridin-4-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(factor Xa inhibitor; preparation of (sulfonylamino)pyrrolidinone factor Xa inhibitors starting from homoserines)

RN 553650-52-5 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[5-[2-(methylsulfonyl)phenyl]-2-pyridinyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI)

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-65-0 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-1-propene-1-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 553650-64-9
CMF C23 H25 Cl F N5 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 553650-67-2 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3'-fluoro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553650-86-5 CAPLUS
CN Benzenesulfonamide, 3-cyano-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-91-2 CAPLUS
CN Glycine, N-[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]-N-[(3S)-1-[5-[2-(methylsulfonyl)phenyl]-2-pyridinyl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-03-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[5-[2-(methylthio)phenyl]-2-thiazolyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-07-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(4-pyridinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 553650-48-9P, (S)-6-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553650-53-6P, (S)-(E)-2-(5-Chlorothien-2-yl)-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]ethenesulfonamide 553650-54-7P, (S)-5-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-1-benzofuran-2-sulfonamide 553650-55-8P, (S)-N-[1-[3-Fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]isoquinoline-5-sulfonamide 553650-56-9P, (S)-(E)-2-(4-Chlorophenyl)-N-[1-[3-

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]ethenesulfonamide 553650-57-0P, (S)-5'-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-2,2'-bithiophene-5-sulfonamide 553650-58-1P, (S)-6-(Dimethylamino)-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553650-59-2P, (S)-N-[1-[3-Fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]quinoline-8-sulfonamide 553650-60-5P, (S)-6-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-1-benzothiophene-2-sulfonamide 553650-61-6P, (S)-5-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-1-benzothiophene-2-sulfonamide 553650-63-8P 553650-66-1P
, (S)-N-[1-[2'-(Aminosulfonyl)-3-fluoro-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-6-chloro-1-benzothiophene-2-sulfonamide 553650-68-3P, (S)-(E)-2-(5-Chlorothien-2-yl)-N-[1-[5-(2-nitrophenyl)pyridin-2-yl]-2-oxopyrrolidin-3-yl]ethenesulfonamide 553650-69-4P, (S)-(E)-2-(5-Chlorothien-2-yl)-N-[1-(3-fluoro-2'-nitro-1,1'-biphenyl-4-yl)-2-oxopyrrolidin-3-yl]ethenesulfonamide 553650-70-7P 553650-71-8P 553650-72-9P,

(S)-(E)-2-(5-Chlorothien-2-yl)-N-[1-[5-[2-[(methylsulfonyl)amino]phenyl]pyridin-2-yl]-2-oxopyrrolidin-3-yl]ethenesulfonamide 553650-73-0P,

(S)-(E)-N-[1-[5-(2-tert-Butylphenyl)pyridin-2-yl]-2-oxopyrrolidin-3-yl]-2-(5-chlorothien-2-yl)ethenesulfonamide 553650-74-1P,
(S)-5-Chloro-N-[1-[5-[2-(methylsulfonyl)phenyl]pyridin-2-yl]-2-oxopyrrolidin-3-yl]-1-benzofuran-2-sulfonamide 553650-75-2P,
(S)-(E)-2-(5-Chlorothien-2-yl)-N-[2-oxo-1-[5-[2-(trifluoromethyl)phenyl]pyridin-2-yl]pyrrolidin-3-yl]ethenesulfonamide 553650-76-3P 553650-77-4P, (S)-(E)-2-(5-Chlorothien-2-yl)-N-[1-[5-(2-cyanophenyl)pyridin-2-yl]-2-oxopyrrolidin-3-yl]ethenesulfonamide 553650-78-5P 553650-79-6P 553650-80-9P 553650-81-0P, (S)-(E)-2-(5-Chlorothien-2-yl)-N-[1-[5-[2-[methyl(methylsulfonyl)amino]phenyl]pyridin-2-yl]-2-oxopyrrolidin-3-yl]ethenesulfonamide 553650-82-1P,

(S)-(E)-2-(5-Chlorothien-2-yl)-N-[1-[5-(2-isopropoxyphenyl)pyridin-2-yl]-2-oxopyrrolidin-3-yl]ethenesulfonamide 553650-83-2P,

(S)-6-Chloro-N-[2-oxo-1-(5-phenylpyridin-2-yl)pyrrolidin-3-yl]naphthalene-2-sulfonamide 553650-84-3P, (S)-5-Chloro-N-[1-[5-[2-(methylsulfonyl)phenyl]pyridin-2-yl]-2-oxopyrrolidin-3-yl]thieno[2,3-b]pyridine-2-sulfonamide 553650-85-4P, (S)-4-Cyano-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]benzenesulfonamide 553650-87-6P, (S)-6-Chloro-N-[1-[3-fluoro-

2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-1-benzofuran-2-sulfonamide 553650-88-7P, (S)-6-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]thieno[3,2-b]pyridine-2-sulfonamide 553650-89-8P, (S)-5-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]thieno[3,2-b]pyridine-2-sulfonamide 553650-90-1P,
(S)-(1E)-2-(5-Chlorothien-2-yl)-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]prop-1-ene-1-sulfonamide 553650-92-3P 553650-94-5P 553650-95-6P

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
553650-96-7P 553650-97-8P 553650-98-9P
553650-99-0P 553651-00-6P 553651-01-7P
553651-04-0P 553651-05-1P, (S)-3-(Aminomethyl)-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]benzenesulfonamide 553651-06-2P, (S)-4-(Aminomethyl)-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]benzenesulfonamide 553651-08-4P, (S)-6-Chloro-N-[1-[4-(2,4-

dimethoxypyrimidin-5-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-09-5P, (S)-6-Chloro-N-[1-[2-fluoro-4-(pyridin-3-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-10-8P, (S)-6-Chloro-N-[1-[2-fluoro-4-(6-methoxypyridin-3-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-11-9P, (S)-6-Chloro-N-[1-[2-fluoro-4-(4-propylpyridin-3-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-12-0P, (S)-6-Chloro-N-[1-[2-fluoro-4-[6-(methylthio)pyridin-3-yl]phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-13-1P, (S)-N-[1-[4-(5-Bromopyridin-3-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]-6-chloronaphthalene-2-sulfonamide 553651-14-2P
, (S)-6-Chloro-N-[1-[2-fluoro-4-(4-methoxypyridin-3-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-15-3P,
(S)-6-Chloro-N-[1-[2-fluoro-4-(pyrimidin-5-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-16-4P, (S)-N-[1-[3'-(Aminomethyl)-3-fluoro-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-6-chloronaphthalene-2-sulfonamide 553651-17-5P,
(S)-6-Chloro-N-[1-[2-fluoro-4-(3-furyl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-18-6P, (S)-6-Chloro-N-[1-[2-fluoro-4-(4-methylthien-2-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-19-7P, (S)-6-Chloro-N-[1-[2-fluoro-4-(thien-3-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-20-0P, (S)-6-Chloro-N-[1-[2-fluoro-4-(5-methylthien-2-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-21-1P, (S)-6-Chloro-N-[1-[2-fluoro-4-(4-methylthien-3-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-22-2P, (S)-6-Chloro-N-[1-[2-fluoro-4-(3-formylthien-2-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-23-3P, (S)-6-Chloro-N-[1-[4-(5-chlorothien-2-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-24-4P, (S)-6-Chloro-N-[1-[4-(3,5-dimethylisoxazol-4-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-25-5P, (S)-6-Chloro-N-[1-[2-fluoro-4-(5-methyl-2-furyl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-26-6P, (S)-6-Chloro-N-[1-(3-fluoro-1,1'-biphenyl-4-yl)-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-28-8P
553651-29-9P, (S)-6-Chloro-N-[1-[2-fluoro-4-(1-oxidopyridin-4-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-30-2P, (S)-6-Chloro-N-[1-[2-fluoro-4-(1-methyl-1H-imidazol-2-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-32-4P, (S)-6-Chloro-N-[1-[4-(2-chloropyridin-3-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-35-7P, (S)-6-Chloro-N-[1-[4-(2-cyanopyridin-3-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-36-8P, (S)-(E)-N-[1-[4-(3-Chloropyridin-4-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]-2-(5-chlorothien-2-yl)ethenesulfonamide 553651-37-9P, (S)-6-Chloro-N-[1-[2-fluoro-4-(pyrimidin-2-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-38-0P, (S)-6-Chloro-N-[1-[4-(3-chloropyridin-2-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-39-1P, (S)-6-Chloro-N-[1-[4-(3-Chloropyridin-4-yl)-2-

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-41-5P, (S)-6-Chloro-N-[1-[2-fluoro-4-(1-methyl-1H-imidazol-4-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide formate
553651-42-6P, (S)-6-Chloro-N-[1-[2-fluoro-4-(1-methyl-1H-imidazol-5-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-43-7P, (S)-2-(5-Chlorothien-2-yl)-N-[1-[3-fluoro-2'-

(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-1,3-thiazole-5-sulfonamide 553651-45-9P, (S)-5-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]thieno[3,2-b]thiophene-2-sulfonamide 553651-46-0P, (S)-2-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]thieno[3,2-b]thiophene-3-sulfonamide 553651-61-9P
553651-80-2P, (S)-6-Chloro-N-[1-[2-fluoro-4-(1H-imidazol-1-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-87-9P, (S)-6-Chloro-N-[1-[2-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-oxopyrrolidin-3-yl]-2-naphthalenesulfonamide
553651-88-0P, (S)-6-Chloro-N-[1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-oxopyrrolidin-3-yl]-2-naphthalenesulfonamide
553651-98-2P 553651-99-3P 553652-01-0P
553652-02-1P, (S)-2-(5-Chlorothien-2-yl)-N-[1-[4-[2-

[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxopyrrolidin-3-yl]ethanesulfonamide 553652-04-3P 553652-06-5P
553652-08-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(factor Xa inhibitor; prepn. of (sulfonylamino)pyrrolidinone factor Xa inhibitors starting from homoserines)
RN 553650-48-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-53-6 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553650-54-7 CAPLUS
CN 2-Benzofuransulfonamide, 5-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-55-8 CAPLUS
CN 5-Isoquinolinesulfonamide, N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-56-9 CAPLUS
CN Ethenesulfonamide, 2-(4-chlorophenyl)-N-[(3S)-1-[3-fluoro-2'-

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553650-59-2 CAPLUS
CN 8-Quinolinesulfonamide, N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-60-5 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-61-6 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-57-0 CAPLUS
CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-58-1 CAPLUS
CN 2-Naphthalenesulfonamide, 6-(dimethylamino)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553650-63-8 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-1-[4-[2-[(dimethylamino)methyl]-

1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]benzo[b]thiophene-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 553650-62-7
CMF C24 H23 Cl F N5 O3 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 553650-66-1 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, N-[(3S)-1-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553650-68-3 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[5-(2-nitrophenyl)-2-pyridinyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-69-4 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-(3-fluoro-2'-nitro[1,1'-biphenyl]-4-yl)-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-70-7 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3'-fluoro-N-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-71-8 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-72-9 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[5-[2-[(methylsulfonyl)amino]phenyl]-2-pyridinyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-73-0 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[5-[2-(1,1-dimethylethyl)phenyl]-2-pyridinyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-74-1 CAPLUS
CN 2-Benzofuransulfonamide, 5-chloro-N-[(3S)-1-[5-[2-(methylsulfonyl)phenyl]-2-pyridinyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-75-2 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-2-oxo-1-[5-[2-(trifluoromethyl)phenyl]-2-pyridinyl]-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-76-3 CAPLUS
CN Benzamide, 2-[6-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-pyridinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-77-4 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[5-(2-cyanophenyl)-2-pyridinyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-78-5 CAPLUS
CN Benzenesulfonamide, 2-[6-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-79-6 CAPLUS
CN Benzenesulfonamide, 2-[6-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-pyridinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553650-80-9 CAPLUS
CN Benzenesulfonamide, 2-[6-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-pyridinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-81-0 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[5-[2-[methyl(methylsulfonyl)amino]phenyl]-2-pyridinyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-82-1 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[5-[2-(1-methylethoxy)phenyl]-2-pyridinyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553650-87-6 CAPLUS
CN 2-Benzofuransulfonamide, 6-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-88-7 CAPLUS
CN Thieno[3,2-b]pyridine-2-sulfonamide, 6-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-83-2 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(5-phenyl-2-pyridinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-84-3 CAPLUS
CN Thieno[2,3-b]pyridine-2-sulfonamide, 5-chloro-N-[(3S)-1-[5-[2-(methylsulfonyl)phenyl]-2-pyridinyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-85-4 CAPLUS
CN Benzenesulfonamide, 4-cyano-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553650-89-8 CAPLUS
CN Thieno[3,2-b]pyridine-2-sulfonamide, 5-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-90-1 CAPLUS
CN 1-Propene-1-sulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-92-3 CAPLUS
CN Glycine, N-[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]-N-[(3S)-1-[5-[2-(methylsulfonyl)phenyl]-2-pyridinyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Double bond geometry as shown.



RN 553650-94-5 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[5-[2-(methylsulfonyl)phenyl]-2-pyridinyl]-2-oxo-3-pyrrolidinyl]-N-[2-(4-morpholinyl)ethyl]ethenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 553650-93-4
CMF C28 H31 Cl N4 O6 S3

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 553650-95-6 CAPLUS
CN Acetamide, 2-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl][(3S)-1-[5-[2-(methylsulfonyl)phenyl]-2-pyridinyl]-2-oxo-3-pyrrolidinyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Acetamide, 2-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl][(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-99-0 CAPLUS
CN Glycine, N-[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-00-6 CAPLUS
CN Glycine, N-[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-01-7 CAPLUS
CN [1,1'-Biphenyl]-3-carboxamide, 4'-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3'-fluoro- (9CI) (CA

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-96-7 CAPLUS
CN Carbamic acid, [[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl][(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-97-8 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-N-[2-(4-morpholinyl)ethyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-98-9 CAPLUS

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
INDEX NAME)

Absolute stereochemistry.



RN 553651-04-0 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[5-[2-(methylsulfonyl)phenyl]-2-thiazolyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-05-1 CAPLUS
CN Benzenesulfonamide, 3-(aminomethyl)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-06-2 CAPLUS
CN Benzenesulfonamide, 4-(aminomethyl)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-08-4 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(2,4-dimethoxy-5-pyrimidinyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-09-5 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(3-pyridinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-10-8 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(6-methoxy-3-pyridinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-11-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(4-propyl-3-pyridinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-12-0 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-[6-(methylthio)-3-pyridinyl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-13-1 CAPLUS
CN 2-Naphthalenesulfonamide, N-[(3S)-1-[4-(5-bromo-3-pyridinyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-14-2 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(4-methoxy-3-pyridinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-15-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(5-pyrimidinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-16-4 CAPLUS
CN 2-Naphthalenesulfonamide, N-[(3S)-1-[3'-(aminomethyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-17-5 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(3-furanyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-18-6 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(4-methyl-2-thienyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-19-7 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(3-thienyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-20-0 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(5-methyl-2-thienyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-21-1 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(4-methyl-3-thienyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-22-2 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(3-formyl-2-thienyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-23-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(5-chloro-2-thienyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-24-4 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(3,5-dimethyl-4-isoxazolyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-25-5 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(5-methyl-2-furanyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-26-6 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-(3-fluoro[1,1'-biphenyl]-4-yl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-28-8 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 553651-27-7
CMF C22 H23 Cl F N5 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 553651-29-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1-oxido-4-pyridinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-30-2 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1-methyl-1H-imidazol-2-yl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-37-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(2-pyrimidinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-38-0 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(3-chloro-2-pyridinyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-39-1 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(3-chloro-4-pyridinyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-32-4 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(2-chloro-3-pyridinyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-35-7 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(2-cyano-3-pyridinyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-36-8 CAPLUS
CN Ethenesulfonamide, N-[(3S)-1-[4-(3-chloro-4-pyridinyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-41-5 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-1-[2-fluoro-4-(1-methyl-1H-imidazol-4-yl)phenyl]-2-oxo-3-pyrrolidinyl]-2-naphthalenesulfonamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 553651-40-4
CMF C24 H20 Cl F N4 O3 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 553651-42-6 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1-methyl-1H-imidazol-5-yl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-43-7 CAPLUS
CN 5-Thiazolesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-45-9 CAPLUS
CN Thieno[3,2-b]thiophene-2-sulfonamide, 5-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-46-0 CAPLUS
CN Thieno[3,2-b]thiophene-3-sulfonamide, 2-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-88-0 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-98-2 CAPLUS
CN Acetamide, 2-[[1-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl][[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 553651-99-3 CAPLUS
CN Acetamide, 2-[[1-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl][[(1Z)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-61-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-80-2 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1H-imidazol-1-yl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-87-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553652-01-0 CAPLUS
CN Formic acid, compd. with 2-[[(3S)-1-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl][(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]acetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 553652-00-9
CMF C26 H22 Cl F N4 O6 S3

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 553652-02-1 CAPLUS
CN 2-Thiopheneethanesulfonamide, 5-chloro-N-[(3S)-1-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553652-04-3 CAPLUS
CN 1H-Imidazole-2-methanaminium,
N-(2-amino-2-oxoethyl)-1-[4-[(3S)-3-[[[(1E)-

2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]-N,N-dimethyl-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 553652-03-2
CMF C25 H29 Cl F N6 O4 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 71-47-6
CMF C H O2

O=CH-O-

RN 553652-06-5 CAPLUS
CN 1H-Imidazole-2-methanaminium,
N-(2-amino-2-oxoethyl)-1-[4-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]-N,N-dimethyl-, formate (9CI) (CA INDEX NAME)

CM 1

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

O=CH-O-

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 553652-05-4
CMF C24 H29 Cl F N6 O4 S2

Absolute stereochemistry.



CM 2

CRN 71-47-6
CMF C H O2

O=CH-O-

RN 553652-08-7 CAPLUS
CN 1H-Imidazole-2-methanaminium, N-(2-amino-2-oxoethyl)-1-[4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]-N,N-dimethyl-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 553652-07-6
CMF C26 H27 Cl F N6 O4 S2

Absolute stereochemistry.



CM 2

CRN 71-47-6
CMF C H O2